As the first approved PARP inhibitor, olaparib has been validated in multiple clinical trials for its efficacy in patients with BRCA mutations and homologous recombination deficiency (HRD). Here, PARP1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.